Conference
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.
Authors
Harb WA; Sessa C; Hirte HW; Kaye SB; Simantov R; Banerjee SN; Christinat A; Sternberg DW; Singh M; Light R
Volume
29
Pagination
pp. 3099-3099
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.3099
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X